Competitive or noncompetitive, that's the question: research toward histone deacetylase inhibitors
Authors:
Open Access
- 1 May 2008
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 7 (5) , 1007-1012
Abstract
Histone deacetylase (HDAC) catalyze deacetylation of acetylated lysine residues on histones and a growing number of nonhistone proteins including many transcription factors, playing an important role in the upstream control of gene transcription, cell cycle progression, and apoptosis. It has been wildly recognized that HDACs are promising targets for cancer therapy. At least 10 HDAC inhibitors are currently in clinical evaluation. However, none of them is practically isoform selective. More and more evidence suggests that acetylation modification occurring in ∼85% of eukaryotic proteins should be a general mechanism for altering protein structures or protein-protein interactions. Unselectively inhibiting the deacetylation activity of HDACs and the consequent modulation of the acetylation status of so many substrates might have multiple mechanisms of action in vivo, resulting in both therapeutic responses and unanticipated side effects. Lack of selectivity for the existing HDAC inhibitors is somewhat logical for the highly conserved residues in the catalytic site and the malleable structure in the rim of the active site of HDAC enzymes. For further advancements in the development of HDAC inhibitors, clues for selectivity will have to be considered. [Mol Cancer Ther 2008;7(5):1007–12]Keywords
This publication has 54 references indexed in Scilit:
- Role for Histone Deacetylase 1 in Human Tumor Cell ProliferationMolecular and Cellular Biology, 2007
- Complex structure of a bacterial class 2 histone deacetylase homologue with a trifluoromethylketone inhibitorActa Crystallographica Section F Structural Biology and Crystallization Communications, 2007
- HDAC Inhibitors and Cardiac SafetyClinical Cancer Research, 2007
- c-Jun Downregulation by HDAC3-Dependent Transcriptional Repression Promotes Osmotic Stress-Induced Cell ApoptosisMolecular Cell, 2007
- Cardiac Studies in Patients Treated with Depsipeptide, FK228, in a Phase II Trial for T-Cell LymphomaClinical Cancer Research, 2006
- Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancerNature Reviews Cancer, 2006
- Epigenetics in human disease and prospects for epigenetic therapyNature, 2004
- Molecular Evolution of the Histone Deacetylase Family: Functional Implications of Phylogenetic AnalysisJournal of Molecular Biology, 2004
- Upregulation and Nuclear Recruitment of HDAC1 in Hormone Refractory Prostate CancerThe Prostate, 2004
- Translating the Histone CodeScience, 2001